Assenagon Asset Management S.A. Has $12.20 Million Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Assenagon Asset Management S.A. lessened its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 37.3% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 146,082 shares of the biopharmaceutical company's stock after selling 86,851 shares during the period. Assenagon Asset Management S.A. owned 0.14% of Intra-Cellular Therapies worth $12,201,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the stock. Wasatch Advisors LP boosted its stake in shares of Intra-Cellular Therapies by 3.5% in the third quarter. Wasatch Advisors LP now owns 3,848,588 shares of the biopharmaceutical company's stock valued at $281,601,000 after buying an additional 130,351 shares in the last quarter. Avoro Capital Advisors LLC lifted its stake in Intra-Cellular Therapies by 21.2% in the 2nd quarter. Avoro Capital Advisors LLC now owns 3,000,000 shares of the biopharmaceutical company's stock valued at $205,470,000 after buying an additional 525,000 shares in the last quarter. Bellevue Group AG increased its position in Intra-Cellular Therapies by 0.6% during the third quarter. Bellevue Group AG now owns 2,485,627 shares of the biopharmaceutical company's stock worth $181,873,000 after buying an additional 14,342 shares in the last quarter. State Street Corp raised its holdings in shares of Intra-Cellular Therapies by 3.1% in the third quarter. State Street Corp now owns 1,858,915 shares of the biopharmaceutical company's stock worth $136,017,000 after acquiring an additional 56,664 shares during the last quarter. Finally, Franklin Resources Inc. boosted its stake in shares of Intra-Cellular Therapies by 9.7% during the third quarter. Franklin Resources Inc. now owns 1,753,286 shares of the biopharmaceutical company's stock valued at $129,463,000 after acquiring an additional 155,655 shares during the last quarter. 92.33% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Baird R W downgraded shares of Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research note on Monday, January 13th. Leerink Partnrs cut Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a report on Monday, January 13th. Needham & Company LLC reiterated a "hold" rating and set a $100.00 target price on shares of Intra-Cellular Therapies in a report on Monday, January 13th. Piper Sandler reaffirmed a "neutral" rating and issued a $132.00 price objective (up previously from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. Finally, Morgan Stanley lifted their price target on shares of Intra-Cellular Therapies from $92.00 to $95.00 and gave the stock an "overweight" rating in a research note on Friday, October 11th. Six investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Intra-Cellular Therapies presently has a consensus rating of "Moderate Buy" and an average price target of $100.31.

Intra-Cellular Therapies Trading Down 0.0 %

ITCI stock traded down $0.06 during trading hours on Friday, hitting $126.20. 6,016,325 shares of the stock traded hands, compared to its average volume of 451,954. The stock has a 50-day simple moving average of $89.30 and a 200 day simple moving average of $80.81. Intra-Cellular Therapies, Inc. has a one year low of $62.78 and a one year high of $128.00.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last released its earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.07). The business had revenue of $175.40 million during the quarter, compared to the consensus estimate of $172.30 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The firm's revenue for the quarter was up 39.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.25) earnings per share. On average, sell-side analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Insider Transactions at Intra-Cellular Therapies

In other news, CEO Sharon Mates sold 51,000 shares of the business's stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the sale, the chief executive officer now owns 1,070,329 shares in the company, valued at $91,834,228.20. The trade was a 4.55 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, President Michael Halstead sold 22,869 shares of Intra-Cellular Therapies stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $89.12, for a total transaction of $2,038,085.28. The disclosure for this sale can be found here. Corporate insiders own 2.60% of the company's stock.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.